文献速递乳腺癌

c-TRAK TN试验结果:利用ctDNA突变追踪检测分子残留病灶并触发干预的中高危早期三阴性乳腺癌临床试验

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2022-11-22

c-TRAK TN是一项多中心II期试验,对早期三阴性乳腺癌患者进行前瞻性ctDNA监测,ctDNA阳性者按2:1随机分配至干预组或观察组。12个月内ctDNA检出率为27.3%(44/161,95%CI 20.6%–34.9%)。干预组中72%(23/32)在ctDNA阳性时分期扫描已见转移,开始帕博利珠单抗的5例患者均未达到持续ctDNA清除。

要点

  • 早期TNBC患者12个月内ctDNA检出率为27.3%(44/161,95%CI 20.6%–34.9%)。
  • 干预组72%(23/32)在ctDNA阳性时分期扫描已发现转移。
  • 开始帕博利珠单抗的5例患者均未达到持续ctDNA清除。

核心结论

  • c-TRAK TN是首个评估ctDNA检测在TNBC治疗指导中临床效用的前瞻性研究。
  • 患者在ctDNA检出时转移性疾病比例高。
  • 研究结果对未来试验设计有启示,强调应尽早开始ctDNA检测,并采用更敏感和/或更频繁的ctDNA检测方案。

研究设计与样本

  • c-TRAK TN为多中心II期试验,整合数字PCR前瞻性ctDNA监测。
  • 纳入新辅助化疗后有残留病灶的早期TNBC患者,或接受辅助化疗的II/III期患者。
  • ctDNA监测包括每3个月采血至12个月(若因冠状病毒病错过样本则至18个月)。
  • ctDNA阳性患者按2:1随机分配至干预组与观察组。
  • ctDNA结果设盲,除非患者分配至干预组,此时进行分期扫描,无复发者接受帕博利珠单抗。

主要发现

  • 2018年1月30日至2019年12月6日共登记208例患者,185例肿瘤测序,171例(92.4%)有可追踪突变,161例进入ctDNA监测。
  • 12个月内ctDNA检出率为27.3%(44/161,95%CI 20.6%–34.9%)。
  • 7例患者在无既往ctDNA检出情况下复发。
  • 45例患者进入治疗部分(干预组n=31;观察组n=14;1例观察组患者在方案修订后重新分配至干预组)。
  • 分配至干预组的患者中,72%(23/32)在ctDNA阳性时分期扫描显示转移,4例拒绝帕博利珠单抗。

关键数值与推荐

  • 12个月内ctDNA检出率为27.3%(44/161,95%CI 20.6%–34.9%)。
  • 干预组中72%(23/32)在ctDNA阳性时分期扫描发现转移。
  • 开始帕博利珠单抗的5例患者中,持续ctDNA清除率为0例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK TN assessed the utility of prospective ctDNA surveillance in TNBC and the activity of pembrolizumab in patients with ctDNA detected [ctDNA positive (ctDNA+)]. PATIENTS AND METHODS: c-TRAK TN, a multicentre phase II trial, with integrated prospective ctDNA surveillance by digital PCR, enrolled patients with early-stage TNBC and residual disease following neoadjuvant chemotherapy, or stage II/III with adjuvant chemotherapy. ctDNA surveillance comprised three-monthly blood sampling to 12 months (18 months if samples were missed due to coronavirus disease), and ctDNA+ patients were randomised 2 : 1 to intervention : observation. ctDNA results were blinded unless patients were allocated to intervention, when staging scans were done and those free of recurrence were offered pembrolizumab. A protocol amendment (16 September 2020) closed the observation group; all subsequent ctDNA+ patients were allocated to intervention. Co-primary endpoints were (i) ctDNA detection rate and (ii) sustained ctDNA clearance rate on pembrolizumab (NCT03145961). RESULTS: Two hundred and eight patients registered between 30 January 2018 and 06 December 2019, 185 had tumour sequenced, 171 (92.4%) had trackable mutations, and 161 entered ctDNA surveillance. Rate of ctDNA detection by 12 months was 27.3% (44/161, 95% confidence interval 20.6% to 34.9%). Seven patients relapsed without prior ctDNA detection. Forty-five patients entered the therapeutic component (intervention n = 31; observation n = 14; one observation patient was re-allocated to intervention following protocol amendment). Of patients allocated to intervention, 72% (23/32) had metastases on staging at the time of ctDNA+, and 4 patients declined pembrolizumab. Of the five patients who commenced pembrolizumab, none achieved sustained ctDNA clearance. CONCLUSIONS: c-TRAK TN is the first prospective study to assess whether ctDNA assays have clinical utility in guiding therapy in TNBC. Patients had a high rate of metastatic disease on ctDNA detection. Findings have implications for future trial design, emphasising the importance of commencing ctDNA testing early, with more sensitive and/or frequent ctDNA testing regimes.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Turner NC, Swift C, Jenkins B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2022. PMID: 36423745. doi:10.1016/j.annonc.2022.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。